Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy

• Autoři: FORDE S.; MATTHEWS J.D.; JAHANGIRI L.; LEE L.; PROKOPH N.; MALCOLM T.I.; GIGER O.; BELL N.; BLAIR H.; O'MARCAIGH A.; SMITH O.; KENNER L.; BOMKEN S.; BURKE G.A.A.; TURNER Suzanne Dawn
• Rok publikování: 2021
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: BRITISH JOURNAL OF HAEMATOLOGY
• Fakulta / Pracoviště MU: Středoevropský technologický institut
• www: https://onlinelibrary.wiley.com/doi/10.1111/bjh.17043
• Doi: http://dx.doi.org/10.1111/bjh.17043
• Klíčová slova: Burkitt lymphomapatient derived xenograftrelapseB-cell lymphomamurine cancer models
• Popis: Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by aMYCtranslocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.